GeneDx Holdings (WGSWW) Equity Average (2020 - 2026)

GeneDx Holdings has disclosed Equity Average across 7 years of filings, most recently posting $281.2 million for Q1 2026.

• In Q1 2026, Equity Average rose 11.87% year-over-year to $281.2 million; the TTM figure through Mar 2026 stood at $281.2 million (up 11.87% YoY), while the FY2025 annual figure was $276.7 million, up 16.94% from the prior year.
• Equity Average retreated to $281.2 million in Q1 2026, from $300.2 million in the prior quarter.
• Over the last five years, Equity Average for WGSWW reached as high as $599.3 million in Q3 2022 and fell as low as $199.3 million in Q3 2024.
• The 5-year median for Equity Average is $281.2 million (2026), against an average of $305.6 million.
• Annual changes were most pronounced in 2022 — Equity Average soared 783.01% — and 2023, when it slumped 54.08%.
• A 5-year view of Equity Average shows it stood at $407.5 million in 2022, then sank by 40.83% to $241.1 million in 2023, then declined by 6.74% to $224.9 million in 2024, then soared by 33.51% to $300.2 million in 2025, then slipped by 6.35% to $281.2 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $281.2 million, $300.2 million, and $284.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.